| Literature DB >> 18647582 |
Abstract
Despite significant success in reducing plasma cholesterol, especially low-density lipoprotein cholesterol, risks for cardiovascular disease (CVD) complications remain. Among these risks are circulating levels of oxidative modified lipoproteins, primarily oxidized low-density lipoproteins (oxLDL). The evidence supporting oxLDL as a potential target for therapeutic management to reduce metabolic complications and CVD events is reviewed in this report.Entities:
Year: 2008 PMID: 18647582 DOI: 10.1007/s11936-008-0047-4
Source DB: PubMed Journal: Curr Treat Options Cardiovasc Med ISSN: 1092-8464